Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects

Academic Article

Abstract

  • HAART has decreased the incidence of AIDS and death among HIV-infected individuals dramatically. This approach often becomes cumbersome to patients, involving multiple drugs administered on varying schedules. We investigated the pharmacokinetics, efficacy, and tolerability of a once-daily regimen of fosamprenavir, tenofovir, emtricitabine and ritonavir in HIV-infected treatment-naive subjects. No clinically significant interaction between the drugs was noted, and the regimen showed good efficacy and tolerability over the course of 48 weeks. © 2007 Lippincott Williams & Wilkins, Inc.
  • Published In

  • AIDS  Journal
  • Digital Object Identifier (doi)

    Author List

  • Parks DA; Jennings HC; Taylor CW; Acosta EP
  • Start Page

  • 1373
  • End Page

  • 1375
  • Volume

  • 21
  • Issue

  • 10